CTRI/2022/06/043101招募中未知
A multicenter, open label, balanced, randomized, two-treatment, three-period, three sequence, partial replicate, single dose, cross-over bioequivalence study of Doxorubicin Hydrochloride pegylated liposomal 2 mg/ml concentrate for solution for infusion (20 mg/10 ml) of TTY Biopharm Company Ltd., Taiwan R. O. C. with that of Caelyx (Doxorubicin Hydrochloride) pegylated liposomal 2 mg/ml concentrate for solution for infusion (20 mg/10 ml) of Baxter Holding B.V., Netherlands in advanced ovarian cancer patients who have failed a first-line platinum based chemotherapy regimen and/or patients with metastatic breast cancer patients under fed (standardized light meal) condition.
TTY Biopharm Company Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Female patients between 18-65 years of age (both inclusive).
- •2.Ability to understand and provide written informed consent given before the initiation of the pre-study screening prior to participation in the study.
- •3.Patients with advanced ovarian cancer who have failed a first-line platinum-based chemotherapy regimen And/or
- •Patients with metastatic breast cancer who require Doxorubicin Hydrochloride (Pegylated liposomal) for treatment that are already receiving or scheduled to start Doxorubicin Hydrochloride (Pegylated liposomal) in the dose of 50 mg/m2 dose as monotherapy.
- •4.Cardiac function (left ventricular ejection fraction [LVEF]) ââ?°Â¥50%.
- •5.Patient should have recovered from any toxic effects of previous chemotherapy as judged by the Investigator.
- •6.Patients with life expectancy of at least 6 months.
- •7.Able to comply with study requirement in opinion of Principal Investigator.
- •8.Adequate Hematopoietic, Renal and Liver function defined as the following:
- •Bone marrow function:
- •ANC more than or equal 1500/mm3
- •Platelet count more than equal 100,000/mm3
- •Haemoglobin ââ?°Â¥ 9.0 g/dl
- •Renal function:Serum Creatinine ââ?°Â¤ 1.5 x ULN
- •Hepatic function
- •AST and ALT ââ?°Â¤ 3 x ULN (ââ?°Â¤5Ã?â?? ULN for liver metastasis)
- •Alkaline phosphatase ââ?°Â¤ 2.5 x ULN (ââ?°Â¤5 Ã?â?? ULN for bone metastasis and ââ?°Â¤4 Ã?â?? ULN for liver metastasis)
- •Total Bilirubin < 1.2 mg/dL (ââ?°Â¤4 Ã?â?? ULN for liver metastasis)
- •9.Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of minor surgery; at least 4 weeks must have elapsed from the time of major surgery.
- •10.Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months
- •prior to Study drug administration] sexual partner) during study and up to 6 months after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
排除标准
- •1.Patients who are:
- •Ã¢â?¬Â¢Pregnant
- •Ã¢â?¬Â¢Breast feeding
- •Ã¢â?¬Â¢Of childbearing potential with a positive pregnancy test at screening (serum) and prior to dosing (urine) in Period I.
- •Ã¢â?¬Â¢Female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial
- •2.Patients with an ECOG (Eastern Cooperative Oncology group) Performance Status Score >3.
- •3.If total cumulative dose (lifetime exposure) of Doxorubicin approaches 450 mg/m2.
- •4.Active opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, P.carinii or other microorganism if under treatment with myelotoxic drugs.
- •5.Clinically significant liver or kidney disorders.
- •6.Patients with severe ascites and pleural exudates.
- •7.Impaired cardiac function including any of the following conditions within past 6 months:
- •a.Unstable angina
- •b.QTc prolongation ( >450 msec) or other significant ECG abnormalities.
- •c.Coronary artery bypass graft surgery.
- •d.Symptomatic peripheral vascular disease.
- •e.Myocardial infarction
- •f.NYHA class II-IV heart failure
- •g.Severe uncontrolled ventricular arrhythmias
- •h.Clinically significant pericardial disease
- •i.Electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
- •j.Patients with evidence of abnormal cardiac conduction (e.g., bundle branch block or heart block) are eligible if their disease has been stable for the past six months.
- •k.Severe uncontrolled arrhythmias.
- •8.History of hypersensitivity reactions attributed to a conventional formulation of Doxorubicin Hydrochloride pegylated liposomal or the components of CaelyxÃ?®.
- •9.Use of any recreational drugs or history of drug addiction.
- •10.Known brain metastasis.
- •11.Pre-existing motor or sensory neurotoxicity of a severity ââ?°Â¥ grade 2 by NCI criteria.
- •12.Other serious illness or medical condition that would prohibit the understanding and giving of informed consent.
- •13.A positive hepatitis screen including hepatitis B surface antigen, HCV and HAV antibodies.
- •14.A positive test result for HIV antibody and/or syphilis (VDRL/RPR) test.
- •8.History of hypersensitivity reactions attributed to a conventional formulation of Doxorubicin Hydrochloride pegylated liposomal or the components of CaelyxÃ?®.
- •9.Use of any recreational drugs or history of drug addiction.
- •10.Known brain metastasis.
- •11.Pre-existing motor or sensory neurotoxicity of a severity ââ?°Â¥ grade 2 by NCI criteria.
- •12.Other serious illness or medical condition that would prohibit the understanding and giving of informed consent.
- •13.A positive hepatitis screen including hepatitis B surface antigen, HCV and HAV antibodies.
- •14.A positive test result for HIV antibody and/or syphilis (VDRL/RPR) test.
- •8.History of hypersensitivity reactions attributed to a conventional formulation of Doxorubicin Hydrochloride pegylated liposomal or the components of CaelyxÃ?®.
- •9.Use of any recreational drugs or history of drug addiction.
- •10.Known brain metastasis.
- •11.Pre-existing motor or sensory neurotoxicity of a severity ââ?°Â¥ grade 2 by NCI criteria.
- •12.Other serious illness or medical condition that would prohibit the unde
研究者
相似试验
已完成
不适用
A multicenter, open label, balanced, randomized, two-treatment, two- period, two-sequence, cross-over bioequivalence study of Pegylated Liposomal Doxorubicin HCl injection with that of Doxil® in ovarian cancer patients under fasting condition.CTRI/2014/08/004832Intas Pharmaceuticals Ltd48
已完成
不适用
Bioequivalence study of Risperidone in patients with schizophrenia or bipolar I disorder.CTRI/2018/09/015704Qilu Pharmaceutical Co Ltd24
进行中（未招募）
不适用
A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets, compared to Viramune 400 mg prolonged release tablets in adult HIV1 infected patients.CTRI/2015/10/006244Amneal Pharmaceuticals Company GmbH
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Dr. Reddyâ??s Laboratories, with that of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Sun Pharmaceutical Ind., in ovarian cancer patientsCTRI/2014/06/004703Dr Reddys Laboratories Limited60
进行中（未招募）
不适用
Study of Paliperidone Palmitate injection 156mg/mL with INVEGA SUSTENNA® Injectable Suspension 156mg/mL in subjects with schizophrenia.CTRI/2020/05/025244Qilu Pharmaceutical Co Ltd